Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 34  |  Issue : 2  |  Page : 576-581

Prognosis of vascular endothelial growth factor gene polymorphism in Egyptian patients with acute myeloid leukemia


1 Department of Zoology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt
3 Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Menoufia, Egypt

Correspondence Address:
Hagar A Alagizy
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Menoufia University, Menoufia
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_151_20

Rights and Permissions

Background Angiogenesis is an important process in hematological malignancies especially leukemia. Its role in acute leukemia has been discussed since the cloning of the vascular endothelial growth factor (VEGF) gene from acute myelogenous leukemia (AML). HL-60 is a human promyelocytic leukemia cell line. VEGF, a polymorphic gene, plays a key role in angiogenesis and tumor growth. Its different genotypes are associated with many human diseases. Increased angiogenesis, mediated by VEGF, was associated with poor prognosis in AML patients. AML that arises from neoplastic transformation of hematopoietic stem and progenitor cells remains one of the greater challenges in treating this AML. In adults, leukemia is included in the top 15 of the most common forms of cancer. Single-nucleotide polymorphism of the VEGF gene, 699947 is found in peripheral blood mononuclear cells of Iranian, Australian, Caucasian, and African patients with AML. The main target of this study is to investigate the relationship between VEGF gene polymorphism (rs699947) with AML. Patients and methods This a controlled study which included 100 and 76 individuals in each group, respectively. Group 1: a healthy control group and group 2: AML diagnosed patients. Blood samples were genotyped using the tetra-primer amplification-refractory mutation system-PCR and the results were confirmed by PCR-restriction fragment length polymorphism method. Results Our results suggest that there is a correlation between rs699947 single-nucleotide polymorphism and AML development and prognosis. However, patients with −2578 AA/CC genotypes were associated with significant better complete remission in comparison to patients with −2578 CA genotype (P = 0.0001). We found that certain polymorphisms are associated significantly with remissions while others with worse response to induction chemotherapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed966    
    Printed18    
    Emailed0    
    PDF Downloaded110    
    Comments [Add]    

Recommend this journal